- Active, not recruiting
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
Updated: Feb 10
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Sponsor
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04184050
Official Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
First Posted : December 3, 2019
Click here to see details on ClinicalTrials.gov
Drug: HPN217
BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 (Code C171631)
Anti-BCMA/CD3e TriTAC HPN217
BCMA/CD3 Tri-specific T-cell Activating Construct HPN217
BCMA/CD3e Tri-specific T-cell Activating Construct HPN217
BCMA/CD3e TriTAC HPN217
BCMA/CD3e-specific TriTAC HPN217
HPN 217
HPN-217
HPN217
TriTAC HPN217
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I
Hematology Disease Topics & Pathways:
Biological, Adult, Diseases, Therapies, immunotherapy, Study Population, Clinically relevant
Saturday, December 5, 2020, 7:00 AM-3:30 PM
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Kansas
United States, New York
United States, Oregon
United States, Washington
Europe
France
Germany
Spain